Health Canada accepts Kashiv’s ADL-018 filing for Xolair biosimilar
Bottom line
Version 1
Health Canada has validated and accepted the market authorization application for Kashiv BioSciences’ ADL-018, a proposed biosimilar to Xolair (omalizumab), giving the company a formal regulatory foothold in Canada as it pushes the product across multiple markets. Kashiv said ADL-018 is being developed with Alvotech for Canada and other ex-U.S. territories, while Amneal is tied to U.S. commercialization. The filing follows earlier Phase 1 data, completion of Phase 3 enrollment, and positive topline confirmatory efficacy and safety results reported in chronic spontaneous urticaria. In Canada, the move would position ADL-018 against an already approved omalizumab biosimilar, Celltrion’s Omlyclo, which Health Canada cleared in December 2024. (streetinsider.com)
Why it matters: For veterinary professionals, this is mainly a market signal rather than a practice-changing development. Omalizumab is a human anti-IgE biologic, not a veterinary medicine, but biosimilar competition can still matter to clinics that track specialty-pharma pricing, client expectations, and broader biologics policy. Health Canada says biosimilars must show high similarity to the reference biologic and no clinically meaningful differences in safety and efficacy, so acceptance means the dossier is complete enough for review, not that approval has been granted. (canada.ca)
What to watch: Watch for whether Health Canada grants approval, what indications ADL-018 ultimately carries in Canada, and whether it can differentiate itself in a market where Omlyclo already has first-mover status. (businesswire.com)
Key facts
- Product
- ADL-018
- Reference biologic
- Xolair (omalizumab)
- Regulatory status in Canada
- Health Canada accepted the market authorization application
- Meaning of acceptance
- Cleared the initial validation screen; not approval
- Developer
- Kashiv BioSciences
- Canadian competitor
- Celltrion’s Omlyclo
- Omlyclo Canada approval
- December 2024
- Development status
- Phase 3 enrollment completed in July 2024
- Study result
- Positive topline confirmatory efficacy and safety results in chronic spontaneous urticaria
Version 2
Health Canada has accepted Kashiv BioSciences’ market authorization application for ADL-018, the company’s proposed biosimilar to Xolair (omalizumab), marking the latest regulatory step for a product that’s being advanced as part of a broader multinational rollout. The acceptance does not mean approval, but it confirms the application has cleared the agency’s initial validation screen and can move into formal review. (streetinsider.com)
The filing lands in a market that’s already moving. Xolair, an anti-IgE monoclonal antibody, has longstanding human indications in allergic asthma and chronic spontaneous urticaria, and in the U.S. it also gained a food allergy indication in February 2024. Canada’s biosimilar framework allows authorization when a sponsor shows a product is highly similar to the reference biologic and has no clinically meaningful differences in safety or efficacy. That framework has already produced one omalizumab biosimilar entrant: Celltrion’s Omlyclo, which Health Canada approved in December 2024 and which was still described in early 2026 as the only approved omalizumab biosimilar in Canada. (fda.gov)
ADL-018 has been in development for several years. Kashiv reported successful Phase 1 study results in 2023, then announced Phase 3 enrollment completion in July 2024 for a confirmatory trial in chronic spontaneous urticaria. In June 2025, the company reported positive topline results from that confirmatory efficacy and safety study, saying the candidate met its primary endpoint. The same asset has also moved through other regulators: Kashiv said the FDA accepted its biologics license application and the European Medicines Agency accepted its filing in September 2025, while the UK MHRA accepted its application in March 2025. (businesswire.com)
The partnership structure is also important. Kashiv and Alvotech signed an exclusive licensing agreement in 2023 covering development and commercialization of the proposed omalizumab biosimilar across the European Economic Area, the UK, Switzerland, Australia, New Zealand, and Canada. Separately, Kashiv entered an exclusive agreement with Amneal tied to U.S. commercialization. That suggests the Canadian filing is part of a coordinated territory-by-territory strategy rather than a stand-alone move. (businesswire.com)
Public expert commentary on this specific Canadian acceptance appears limited so far, but the broader industry view is clear: omalizumab is now a competitive biosimilar category. FDA records show Omlyclo became the first interchangeable biosimilar to Xolair in the U.S. in March 2025, and payer pipeline trackers have already framed ADL-018 as a potential follow-on entrant rather than a first-to-market product. That competitive backdrop could shape pricing, formulary negotiations, and uptake if ADL-018 reaches approval in Canada. (fda.gov)
Why it matters: For veterinary professionals, this is not about an imminent new animal therapy. It matters more as a readout on the biologics market that increasingly influences client expectations around specialty medicines, substitution, and affordability. Many veterinary teams are fielding more questions from pet parents who are familiar with human biologics and biosimilars, especially in dermatology, allergy, and immunology-adjacent care. Developments like this can help frame conversations about what biosimilar review actually means, what “accepted for review” does and does not signal, and how competition can affect access over time. (canada.ca)
There’s also a practical policy angle. Health Canada’s biosimilar guidance emphasizes that authorization decisions are based on a full benefit-risk assessment, and indications may be granted based on the totality of evidence for the reference biologic. For clinicians and practice leaders watching cross-border drug policy, ADL-018 is another example of how biosimilar pipelines are expanding beyond the earliest oncology and rheumatology targets into allergy and immunology. (canada.ca)
What to watch: The next milestones are a Health Canada review decision, any public disclosure on proposed Canadian indications and labeling, and signs of how ADL-018 would compete with Omlyclo on access, contracting, and formulary positioning if it wins approval. (streetinsider.com)